产品
编 号：F741269
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1781223-80-0
产品详情
生物活性：
Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity.
体内研究：
Telisotuzumab (ABT-700) (i.p., 2.5-40 mg/kg, twice a week, 90 days) 有效拮抗构成性激活的 c-Met 和下游信号，从而抑制 Hs746T 细胞 SCID 小鼠的肿瘤生长。Animal Model:SCID mice with Hs746T cells
Dosage:2.5-40 mg/kg
Administration:i.p., twice a week, 90 days
Result:Reduced total and phosphorylated c-Met as well as phosphorylated Akt and Erk.Complete tumor regression at doses above 10 mg/kg but no effective inhibition of tumor growth at doses below 5mg/kg.
体外研究：
Telisotuzumab (ABT-700) (10 μg/mL, 24 h) 可以抑制 SNU5 细胞的增殖，并导致促凋亡的 Bim 增加和抗凋亡的 Bcl-xL 减少，从而诱发细胞凋亡。
Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity.
体内研究：
Telisotuzumab (ABT-700) (i.p., 2.5-40 mg/kg, twice a week, 90 days) 有效拮抗构成性激活的 c-Met 和下游信号，从而抑制 Hs746T 细胞 SCID 小鼠的肿瘤生长。Animal Model:SCID mice with Hs746T cells
Dosage:2.5-40 mg/kg
Administration:i.p., twice a week, 90 days
Result:Reduced total and phosphorylated c-Met as well as phosphorylated Akt and Erk.Complete tumor regression at doses above 10 mg/kg but no effective inhibition of tumor growth at doses below 5mg/kg.
体外研究：
Telisotuzumab (ABT-700) (10 μg/mL, 24 h) 可以抑制 SNU5 细胞的增殖，并导致促凋亡的 Bim 增加和抗凋亡的 Bcl-xL 减少，从而诱发细胞凋亡。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备